DK1948217T3 - Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom - Google Patents

Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom

Info

Publication number
DK1948217T3
DK1948217T3 DK06780613.3T DK06780613T DK1948217T3 DK 1948217 T3 DK1948217 T3 DK 1948217T3 DK 06780613 T DK06780613 T DK 06780613T DK 1948217 T3 DK1948217 T3 DK 1948217T3
Authority
DK
Denmark
Prior art keywords
disease
parkinson
alzheimer
therapy
growth factor
Prior art date
Application number
DK06780613.3T
Other languages
English (en)
Inventor
Alessandro Lambiase
Stefano Bonini
Original Assignee
Anabasis S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anabasis S R L filed Critical Anabasis S R L
Application granted granted Critical
Publication of DK1948217T3 publication Critical patent/DK1948217T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK06780613.3T 2005-08-19 2006-08-11 Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom DK1948217T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT000447A ITRM20050447A1 (it) 2005-08-19 2005-08-19 Uso del nerve growth factor in collirio nella terapia di patologie del sistema nervoso centrale, quali la malattia di alzheimer e il morbo di parkinson.
PCT/IT2006/000620 WO2007020672A2 (en) 2005-08-19 2006-08-11 Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease

Publications (1)

Publication Number Publication Date
DK1948217T3 true DK1948217T3 (da) 2012-02-20

Family

ID=37667295

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06780613.3T DK1948217T3 (da) 2005-08-19 2006-08-11 Anvendelse af nervevækstfaktor i øjendråber til terapi af patologier af centralnervesystemet såsom Alzheimers og Parkinsons sygdom

Country Status (11)

Country Link
US (1) US20090118177A1 (da)
EP (1) EP1948217B1 (da)
JP (1) JP2009504724A (da)
AT (1) ATE539763T1 (da)
CA (1) CA2619721A1 (da)
DK (1) DK1948217T3 (da)
ES (1) ES2376992T3 (da)
IL (1) IL189605A (da)
IT (1) ITRM20050447A1 (da)
RU (1) RU2429007C2 (da)
WO (1) WO2007020672A2 (da)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101760139B1 (ko) * 2007-06-29 2017-07-31 클라렌슈 피티와이 리미티드 안투여를 통한 신경 또는 신경정신 장애의 치료 또는 예방용 약학 조성물
CN101972224B (zh) * 2010-09-13 2012-01-04 舒泰神（北京）生物制药股份有限公司 一种眼用原位凝胶
IT202000032423A1 (it) 2020-12-24 2022-06-24 Univ Degli Studi Di Trieste Metodo per la produzione di forme processate proteoliticamente di fattori trofici o fattori di crescita

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4959319A (en) * 1985-08-01 1990-09-25 Skelnik Debra L Process of corneal enhancement
US4973466A (en) * 1988-06-21 1990-11-27 Chiron Ophthalmics, Inc. Wound-healing dressings and methods
US5767079A (en) * 1992-07-08 1998-06-16 Celtrix Pharmaceuticals, Inc. Method of treating ophthalmic disorders using TGF -β
US5770577A (en) * 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US6063757A (en) * 1995-11-29 2000-05-16 Urso; Richard G. Wound treatment method with nerve growth factor
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
IT1283911B1 (it) * 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US6299895B1 (en) * 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US6261545B1 (en) * 1996-09-13 2001-07-17 Advanced Medicine Research Institute Ophthalmic compositions of neurotrophic factors, remedies for optic nerve function disorders and method for treating optic nerve function disorders
IT1291892B1 (it) * 1997-04-24 1999-01-21 Alessandro Lambiase Uso del nerve growth factor nella conservazione di cornee in coltura, nella produzione di tessuti corneali e congiuntivali in vitro e nella
AU8559398A (en) * 1998-08-05 2000-02-28 Advanced Medicine Research Institute Remedies for cerebral central lesions with the use of neurotrophic factors
AU2173400A (en) * 1998-12-09 2000-06-26 Chiron Corporation Method for administering agents to the central nervous system
IT1305294B1 (it) * 1999-01-29 2001-05-04 Alessandro Lambiase Uso del nerve growth factor nella terapia di patologie a carico deitessuti intraoculari.
US20020009498A1 (en) * 1999-11-05 2002-01-24 Guy L. Clifton Methods and compositions for treatment of traumatic brain injury
IL147921A0 (en) * 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
RU2251429C2 (ru) * 2002-12-30 2005-05-10 Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) Фармацевтическая композиция для лечения ишемического инсульта и способ лечения

Also Published As

Publication number Publication date
EP1948217A2 (en) 2008-07-30
ATE539763T1 (de) 2012-01-15
RU2429007C2 (ru) 2011-09-20
WO2007020672A3 (en) 2007-05-31
JP2009504724A (ja) 2009-02-05
ITRM20050447A1 (it) 2007-02-20
ES2376992T3 (es) 2012-03-21
WO2007020672A2 (en) 2007-02-22
US20090118177A1 (en) 2009-05-07
IL189605A0 (en) 2008-06-05
IL189605A (en) 2013-10-31
CA2619721A1 (en) 2007-02-22
EP1948217B1 (en) 2012-01-04
RU2008110505A (ru) 2009-09-27

Similar Documents

Publication Publication Date Title
Lucassen et al. Regulation of adult neurogenesis by stress, sleep disruption, exercise and inflammation: Implications for depression and antidepressant action
Stiles et al. The vestibular–basal ganglia connection: Balancing motor control
Fisher et al. AF150 (S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer’s disease
Hu et al. Osthole reverses beta-amyloid peptide cytotoxicity on neural cells by enhancing cyclic AMP response element-binding protein phosphorylation
WO2012006419A3 (en) Pro-neurogenic compounds
Wang et al. Therapeutic strategies for Parkinson’s disease: the ancient meets the future—traditional Chinese herbal medicine, electroacupuncture, gene therapy and stem cells
WO2009132656A3 (en) Crystal structure of human sortilin and uses thereof for identifying ligands to sortilin
MX2012010658A (es) Compuestos de anillo espiro tetraciclico como moduladores de beta-secretasa.
KR20120061421A (ko) 안경 부착형 약물담체 기구장치
Ruff et al. The potential for stem cell therapies to have an impact on cerebral palsy: opportunities and limitations
BR112017022568A2 (pt) compostos e seus usos como inibidores de bace1
Liu et al. Effect of oral administration of Pheretima aspergillum (earthworm) in rats with cerebral infarction induced by middle-cerebral artery occlusion
Wei et al. Geniposide attenuates epilepsy symptoms in a mouse model through the PI3K/Akt/GSK-3β signaling pathway
Guo et al. Use of transcutaneous auricular vagus nerve stimulation as an adjuvant therapy for the depressive symptoms of COVID-19: A literature review
Gao et al. Enhancement of neural regeneration as a therapeutic strategy for Alzheimer's disease
IL189605A0 (en) Use of nerve growth factor in eye-drops for therapy of pathologies of the central nervous system, such as alzheimer's and parkinson's disease
KR101273296B1 (ko) 시신경 자극용 안경
JOP20240081A1 (ar) مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها
Martins-Macedo et al. Adult brain cytogenesis in the context of mood disorders: From neurogenesis to the emergent role of gliogenesis
NO20081675L (no) Cykliske N-[1,3,4]-tiadiazol-2-yl-benzensulfonamlder, fremgangsmate for fremstilling derav og deres anvendelse som farmasoytika
Calne Parkinsonism: Clinical and neuropharmacologic aspects
Wang et al. Cudrania cochinchinensis attenuates amyloid β protein-mediated microglial activation and promotes glia-related clearance of amyloid β protein
Isenmann et al. How to keep injured CNS neurons viable—strategies for neuroprotection and gene transfer to retinal ganglion cells
BR112015000313A2 (pt) piperazino[1,2-a]indol-1-onas e [1,4]diazepino[1,2-a]indol-1-ona
Zhu et al. New progress of isoflurane, sevoflurane and propofol in hypoxic‐ischemic brain injury and related molecular mechanisms based on p75 neurotrophic factor receptor